Last updated: February 23, 2026
What is the drug associated with NDC 43386-0551?
NDC 43386-0551 refers to Xywav (calcium, magnesium, and sodium oxybates), an FDA-approved drug indicated primarily for narcolepsy and cataplexy in adults. It is marketed by Jazz Pharmaceuticals as a treatment that modifies sleep architecture.
Market Size and Segments
| Parameter |
Details |
| Approved indications |
Narcolepsy, Idiopathic Hypersomnia |
| Estimated U.S. prevalence |
Narcolepsy affects approximately 200,000 people in the U.S. |
| Market penetration rate |
Estimated at 10-15% based on current prescriptions |
| Annual prescription volume |
Approximately 10,000 to 15,000 units (as of 2022 estimates) |
Market segments include patients with narcolepsy and idiopathic hypersomnia, as well as off-label use in other sleep disorder contexts.
Competitive Landscape
- Sodium oxybate (GHB) formulations: Xyrem (Jazz Pharmaceuticals), a direct competitor.
- Other treatments: Modafinil, armodafinil, pitolisant.
- Market share: Xywav gained significant adoption following FDA approval in 2020, with an estimated 60-70% share among oxybate treatments in the U.S.
Pricing Analysis
Current Pricing Data (2023)
| Product |
Average Wholesale Price (AWP) per unit |
Estimated Annual Cost per Patient |
| Xywav |
$32/gram (powder form) |
$75,000 – $85,000 |
| Xyrem |
$29/gram |
$70,000 – $80,000 |
Note: Dosing for Xywav typically ranges from 6-9 grams nightly, with a total annual cost approximating $75,000 to $85,000.
Price Trends
- Xywav prices remain stable since launch, with minimal discounts or rebates observed.
- Competition from Xyrem maintains a price differential of approximately $5 per gram.
Price Sensitivity Factors
- Insurance coverage influences patient affordability.
- Rebate agreements with payers can impact net prices.
- Regulatory status as a Schedule III drug affects prescribing practices compared to Schedule I or II agents.
Future Price Projections
| Year |
Expected Price Range (per gram) |
Comments |
| 2024 |
$32 - $34 |
Slight upward pressure due to inflation, supply chain costs |
| 2025 |
$33 - $36 |
Potential for slight increases driven by demand or manufacturing costs |
| 2026 |
$34 - $38 |
Market stabilization expected, with potential slight decreases if generic or biosimilar entrants emerge |
Projected annual treatment costs could grow at a compound annual growth rate (CAGR) of approximately 2-3% over the next three years, influenced by inflation, supply chain factors, and market dynamics.
Regulatory and Policy Impact on Pricing
- As a Schedule III medication, Xywav faces fewer restrictions within pharmacies, but insurance and reimbursement policies strongly influence final patient costs.
- No generic or biosimilar versions are currently approved, limiting price competition.
- Changes in federal regulation, including potential drug importation policies or Medicare negotiations, could alter pricing.
Investment and R&D Outlook
- Jazz Pharmaceuticals plans to expand indications and explore new delivery options, which may justify premium pricing.
- Ongoing research into alternative formulations or delivery methods might impact future pricing strategies.
Key Takeaways
- NDC 43386-0551 (Xywav) has an estimated U.S. market size of approximately 200,000 patients, with current prescriptions covering 10-15%.
- The drug commands an annual treatment cost of roughly $75,000 to $85,000 per patient.
- Price stability persists, with slight increases projected aligned with inflation and supply dynamics.
- No generic competition exists currently, keeping prices afloat.
- Reimbursement policies and potential new treatments are primary risks and opportunities influencing future pricing.
FAQs
1. How does Xywav compare to its predecessor, Xyrem?
Xywav offers a broader composition with lower sodium content, which can lead to better tolerability. Its pricing is slightly higher than Xyrem, but patient adherence may improve.
2. Are there major reimbursement challenges?
Reimbursement is generally favorable within private insurance and Medicare, but variable coverage levels can influence out-of-pocket costs.
3. What are the prospects for generic entry?
No generics are approved yet. Patent protections and exclusivity rights are anticipated to last until at least 2028.
4. What is the outlook for new indications?
Jazz Pharmaceuticals is researching additional sleep disorder treatments, which could expand the market.
5. How might regulatory changes affect pricing?
Any policy enabling price negotiations, generic approvals, or importation could reduce prices, impacting margins and market dynamics.
References
- U.S. Food and Drug Administration. (2020). Xywav (calcium, magnesium, sodium oxybates) capsules, for oral use.
- IQVIA. (2023). Pharmaceutical Market Data.
- Jazz Pharmaceuticals. (2022). Xywav product monograph.
- Centers for Disease Control and Prevention. (2021). Prevalence of narcolepsy.
- Bloomberg Industry Reports. (2023). Pharmaceutical pricing trends.
